AviadoBio Presents New Preclinical Data Validating the vMiX™ Platform for AVB-406 in Alzheimer’s Disease and for AVB-SNCA in Parkinson’s Disease at ESGCT 2026

Contributed by: Business Wire

Logo

Tags

Science

Neurology

Biotechnology

Research

Pharmaceutical

Health

Genetics

Clinical Trials

ESGCT 2026

More Like This

AviadoBio Presents Positive Preclinical Data for AVB-406 Program in Alzheimer’s Disease and Other Tauopathies at ASGCT 2026

AviadoBio Expands vMiX™ Precision Gene Silencing Platform Exclusive License Agreement with King’s College London Beyond Neurological Diseases to All Human Therapeutic Areas

AviadoBio Announces Presentation of Promising Preclinical Safety and Biodistribution Data of its Gene Therapy Candidate AVB-101 for FTD-GRN at the Annual European Society of Gene and Cell Therapy Congress

AviadoBio Advances AVB-101 Gene Therapy Program and Initiates Fourth Dose-Escalation Cohort of Phase 1/2 ASPIRE-FTD Trial

AviadoBio Announces Completion of Second Cohort in Phase 1/2 ASPIRE-FTD Clinical Trial Studying AVB-101 for FTD-GRN

AviadoBio Announces Initiation of Phase 1/2 Clinical Trial, ASPIRE-FTD, Evaluating AVB-101 in People with Frontotemporal Dementia with GRN Mutations

AviadoBio Announces Agreement with Apertura Gene Therapy to License TfR1 CapX™, a Next-Generation Blood-Brain Barrier-Crossing Capsid

AviadoBio Announces First Patient Treated in ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations